doo-TAS-te-ride
Therapeutic Classification: benign prostatic hyperplasia bph agents
Pharmacologic Classification: androgen inhibitors
REMS
Absorption: Well absorbed (60%) following oral administration; also absorbed through skin.
Distribution: 11.5% of serum concentration partitions into semen.
Protein Binding: 99% bound to albumin; 96.6% bound to alpha-1 glycoprotein.
Half-Life: 5 wk.
| ROUTE | ONSET | PEAK | DURATION | |||
|---|---|---|---|---|---|---|
| PO | unknown | 1–2 wk | unknown |
‡Symptoms may only improve over 3–12 mo.
Contraindicated in:
Use Cautiously in:
Derm: rash, urticaria
Endo: gynecomastia
GU: ↓libido, ejaculation disorders, erectile dysfunction, PROSTATE CANCER (HIGH-GRADE), testicular pain, testicular swelling
Neuro: depression
Drug-drug:
Lab Test Considerations:
NDC Code